Correction: J ExpClin Cancer Res 40, 257 (2021)
https://doi.org/10.1186/s13046-021-02050-1
Following publication of the original article [1], author identified an error in Fig. 4a and b, specifically:
-
Figure 4a - Vinculin in MPP89
-
Figure 4b - Tubulin Ist Mes2 and MPP89
The correct figure is presented below:
This correction does not change the result, interpretation, and conclusions of the study. The original article has been corrected.
Reference
Nuvoli B, Antoniani B, Libener R, et al. Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities. J Exp Clin Cancer Res. 2021;40:257. https://doi.org/10.1186/s13046-021-02050-1.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Nuvoli, B., Antoniani, B., Libener, R. et al. Correction: Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities. J Exp Clin Cancer Res 42, 15 (2023). https://doi.org/10.1186/s13046-022-02539-3
Published:
DOI: https://doi.org/10.1186/s13046-022-02539-3